• Impact of vascular biology on cardiovascular
disease, risk prevention, and treatment
Section V: Multiple risk and CV disease prevention
The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.
Volume VI. This edition of the core curriculum is special, because it marks the 10th anniversary of the Vascular Biology Working Group. It covers basic science and clinical advances in vascular biology in a spectrum of disorders. The material is presented in five sections:
This slide/lecture program discusses strategies to prevent cardiovascular disease through aggressive management of multiple risk factors. The focus is on treatment of hypertension and dyslipidemia. The contents provide an update in key areas.
- Recent data showing an epidemic increase in the population at high risk for cardiovascular disease
- New knowledge of basic mechanisms of vascular pathophysiology related to hypertension and dyslipidemia as well as obesity and the metabolic syndrome
- An update on clinical trials that support intensive multifactorial treatment for the reduction of cardiovascular disease
- Important information on statins and safety, including recent data from the FDA
- Latest guidelines for managing hypertension and dyslipidemia as well as for multifactorial risk reduction in high-risk patients
Download 04VBWGCoreMultipleRiskS01.ppt (18 slides - 3.1MB)
Download 04VBWGCoreMultipleRiskS02.ppt (6 slides - 1.5MB)
Download 04VBWGCoreMultipleRiskS03.ppt (24 slides - 4.3MB)
Download 04VBWGCoreMultipleRiskS04.ppt (2 slides - 0.4MB)
Download 04VBWGCoreMultipleRiskS05.ppt (8 slides - 1.2MB)
Download 04VBWGCoreMultipleRiskS06.ppt (19 slides - 3.0MB)
Published by Medical Education Consultants, LLC (MEDCON), on behalf of the University of Florida College of Medicine.
The editorial content of this program does not necessarily reflect the views or recommendations of the University of Florida College of Medicine or AstraZeneca, King Pharmaceuticals Inc, Pfizer Inc, and Wyeth Pharmaceuticals, or the publisher. The reader is advised to consult the full prescribing information of each product prior to use.
This program was prepared and produced by Medical Education Consultants, LLC, Westport, Connecticut, on behalf of the University of
Florida College of Medicine through an unrestricted educational grant provided by AstraZeneca, King Pharmaceuticals Inc, Pfizer Inc, and Wyeth Pharmaceuticals.
©2004 Medical Education Consultants, LLC (MEDCON). All rights reserved.